HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Results for CTL/CD8+ T-Cell Epitope Variants

Filter results by Mutation Type:

VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
VPVWKEATTTLsrASDAKAY gp160(42-61) observed variant
aPVWKEATTTLFCASDAKAY gp160(42-61) observed variant
VPVWKEATTTLFrASDAKAY gp160(42-61) observed variant
VPVWKEATTTLFCvSDAKAY gp160(42-61) observed variant
VPVWKEATTTLFCAtDAKAY gp160(42-61) observed variant
VPVWKEATTTLFyASDAKAY gp160(42-61) observed variant
VPVWKEATTTpFCASDAKAY gp160(42-61) observed variant
VPaWKEATTTLFCASDAKsY gp160(42-61) observed variant
          LFCASDAKAY gp160(52-61) A24 human epitope
          LFCASDAKAY gp160(52-61) A24 human epitope
          LFCASDAKAY gp160(52-61) A24 human epitope
          LFCASDAKAY gp160(52-61) A24 human epitope
          LFCASDAKAY gp160(52-61) A24 human epitope
          LFCASCAKAY gp160(52-61) A24, B38 human epitope
          LFCASDAKAY gp160(52-61) A*24:02 human epitope
          LFCASDAKAY gp160(52-61) A*24:02 human epitope
          LFCASDAKAY gp160(52-61) B*07 human epitope
          LFCASDAKAY gp160(52-61) B*08 human epitope
          LFCASDAKAY gp160(52-61) C*12 human epitope
          LFCASDAKAY gp160(52-61) C*16 human epitope
          LFCASDAKAY gp160(52-61) human epitope
          LFCASDAKAYDTEVHINVWAT gp160(52-71) human epitope
          LFCASDAKAYDTEVHINVWAT gp160(52-71) human epitope
           FCASDAKSY gp160(53-61) B*38:01 human epitope
            CASDAKAYDTEVHNV gp160(54-68) mouse epitope
             ASDAKAYETEVHNVWATH gp160(55-72) human epitope
             ASDAKAHDPEVHNVWATH gp160(55-72) human epitope
             ASDAKAHDPEVyNVWATH gp160(55-72) diminished response
                AKAYETEKHNVW gp160(58-69) human epitope
                 KAYETEVHNVW gp160(59-69) A*23 human epitope
                 KAYETEVHNVW gp160(59-69) A*34 human epitope
                 KAYETEVHNVW gp160(59-69) A*36 human epitope
                 KAYETEVHNVW gp160(59-69) B*37 human epitope
                 KAYETEVHNVW gp160(59-69) B*44 human epitope
                 KAYETEVHNVW gp160(59-69) B*57 human epitope
                 KAYEKEVHNVW gp160(59-69) B*57:03, B*58:01 human epitope
                 KAYETEVHNVW gp160(59-69) B*58 human epitope
                 KAYETEVHNVW gp160(59-69) B*58:01 human epitope
                 KAHDPEVHNVW gp160(59-69) B*58:01 human epitope
                 KAHDPEVyNVW gp160(59-69) diminished response
                 KAYDTEVHNVW gp160(59-69) human epitope
                 KAYeTEVHNVW gp160(59-69) observed variant
                   YETEVHNVW gp160(61-69) B*18 human epitope
                   YkTEVHNVW gp160(61-69) observed variant
                   YEkEVHNVW gp160(61-69) observed variant
                   YgTEVHNVW gp160(61-69) observed variant
                   YqTEVHNVW gp160(61-69) observed variant
                   YEaEVHNVW gp160(61-69) observed variant
                   YEaEVHsVW gp160(61-69) observed variant
                   YETgiHNVW gp160(61-69) observed variant
                   YETEaHNVW gp160(61-69) observed variant; replicative capacity is not abrogated; susceptible form
                   YdTEaHNVW gp160(61-69) escape documented in this paper; replicative capacity/ fitness enhanced; observed variant
                   hETEaHNVW gp160(61-69) observed variant
                   YdTEVHNVW gp160(61-69) escape documented in this paper; replicative capacity/ fitness enhanced; observed variant
                   YdiEVHNVW gp160(61-69) escape documented in this paper; observed variant
                   YETEVHNVW gp160(61-69) B*18:01 human epitope
                   YgTEVHNVW gp160(61-69) diminished response
                   YETEaHNVW gp160(61-69) diminished response
                   YdTEVHNVW gp160(61-69) diminished response
                   YdTEaHNVW gp160(61-69) escape documented in this paper
                   YETEVHNVW gp160(61-69) B*18:01 human epitope
                   YgTEVHNVW gp160(61-69) diminished response
                   YdTEVHNVW gp160(61-69) diminished response
                   YdTEaHNVW gp160(61-69) diminished response
                   YETEVHNVW gp160(61-69) B*18:01 human epitope
                   YETEVHNVW gp160(61-69) B*18:01 human epitope
                   YgTEVHNVW gp160(61-69) diminished response
                   YdTEVHNVW gp160(61-69) diminished response
                   YETEaHNVW gp160(61-69) susceptible form
                   YdTEaHNVW gp160(61-69) diminished response
                    DTEVHNVWATHACVP gp160(62-76) mouse epitope
                    DTEVHNVWATHACVPTDPN gp160(62-80) human epitope
                     KEVHNVWAT gp160(63-71) human epitope
                      EVHNVWATHA gp160(64-73) A*26:03 human epitope
                      EVHNiWATHA gp160(64-73) susceptible form
                      EiHNVWATHA gp160(64-73) diminished HLA binding or increased off-rate; susceptible form
                      EaHNVWATHA gp160(64-73) diminished HLA binding or increased off-rate; susceptible form
                      EmHNVWATHA gp160(64-73) diminished HLA binding or increased off-rate; inferred escape
                      EaHNiWATHA gp160(64-73) observed variant
                      EkHNVWATHA gp160(64-73) diminished HLA binding or increased off-rate
                      gVHNVWATHA gp160(64-73) observed variant
                      EVHNmWATHA gp160(64-73) observed variant
                      EVHNVsATHA gp160(64-73) observed variant
                      EkHNiWATHA gp160(64-73) observed variant
                      EkHNVsATHA gp160(64-73) observed variant
                      EVHNVWAiHA gp160(64-73) observed variant
                      EVHNVWATyA gp160(64-73) observed variant
                      EVHNVWAkHA gp160(64-73) observed variant
                      EVHNVWATqA gp160(64-73) observed variant
                      ErHNVWATHA gp160(64-73) observed variant
                      EVyNiWATHA gp160(64-73) observed variant
                      EqHNVWATHA gp160(64-73) observed variant
                      EqHiVWATHA gp160(64-73) observed variant
                      EaHNVsATHA gp160(64-73) observed variant
                      EgHNVWATHA gp160(64-73) observed variant
                      EVHNaWATHA gp160(64-73) observed variant
                      EVHNtWATHA gp160(64-73) observed variant
                      EVHNVWgTfA gp160(64-73) observed variant
                      gaHNiWATHA gp160(64-73) observed variant
                      EaHNiWAsHA gp160(64-73) observed variant
                      EaHdiWATHA gp160(64-73) observed variant
                      EVHNVWATHv gp160(64-73) observed variant
                      EVHNVWtTHA gp160(64-73) observed variant
                      EmrsiWATHA gp160(64-73) observed variant
                      EVHNVWATHACVPTD gp160(64-78) human epitope
                         NIWATHACV gp160(67-75) A*02 human epitope
                         NIWATHACV gp160(67-75) A*02:01 human epitope
                         NIWATHACV gp160(67-75) A*02:01 transgenic mouse epitope
                         NVWATHACV gp160(67-75) A2 human epitope
                         NiWATHACV gp160(67-75) susceptible form
                         NVWATrACV gp160(67-75) observed variant
                         NiWATrACV gp160(67-75) observed variant
                         NIWATHACV gp160(67-75) A2 human epitope
                         NvWATHACV gp160(67-75) observed variant
                         NIWATHACV gp160(67-75) A2 human epitope
                         NIWATHACV gp160(67-75) A2 human epitope
                         NvWATHACV gp160(67-75) non-susceptible form; susceptible form
                         NVWATHACV gp160(67-75) human epitope
Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health